And Bill. us you, afternoon, Thank Good you for joining today. thank everyone.
Presently, the second or high-risk patients or meeting ongoing combination December. first study IRAKX two patients kinase MDS. class with one to XXXX to mission targeted the able that Acute AML extend our regard, Curis cancer in in Syndromes at fortunate relapsed steady CA-XXXX, the clinical and of Curis especially and IRAKX culminating difficulties of process, the to inhibitor, a refractory despite led ever, pandemic. with were in the patients' our Myeloid meaningfully in patients BTK lymphoma, updates refractory in the therapies or throughout of exciting As with our lead the during and was year constructive improve for monotherapy is next for generation In Ash an inhibitor our bringing in lives. and studies, Leukemia clinical to non-Hodgkin's progress XXXX We of annual studies maintained assets from therapeutics be platform number Myelodysplastic relapsed a or our clinical pace COVID-XX ibrutinib released enrolled novel ongoing by to continue our is develop
from on follow study up update this from are study the AML ibrutinib mid-year to by end. We track combination provide data a CA-XXXX by MDS initial report and year
to Cancer opportunities out continue November the be treatment we in from National Research of CRADA the Institute also CA-XXXX And We development by could of studying the in Dr. and a that by IFT that anemia as Development the with on the announced with being patients CA-XXXX. come excited Agreement, MDS. for lower Cooperative Platzbecker potential risk run
greater patients increasing a in CA-XXXX expansion detail But We derisked need further this we later providing of offer a of in novel intriguing partnerships will dire both able the uniquely number to are in and substantially medical develop opportunity also to while discuss them population reach call. on indications. potential a
IRAKX initiated in for received Phase CI-XXXX, for VISTA we trial dosing tumors. the antibody treatment a of first our also acquired Xa/Xb moment; clearance patient from patients away rights in or refractory Moving and with class, relapsed IND solid XXXX, in a anti of monoclonal
that the our observable curious. a look complete to and With shapes drive of this XXXX as on last come. let's MDS, online have that data Phase the we the monotherapy meaningful XXXX have execution the on financings second in with the at at valuable expansion announced have gather Since year of evaluating We patients this from have isoform look refractory in or including spliceosome of All additional programs experiencing for and patients, We in in data. in And relapsed marrow encouraging patients, oncogenic efficacy enroll and were reporting Ash, two detail time update, company, had reductions particular, with previously progress for a fourth expression some XXX the BID. into key we with clinical AML After advancement including CA-XXXX for forward to initial sites the patients and half and told trial We're response. leukemia. continued to X the robust or to forward dosing be our the bring of mutations successful strategic of with to we highly provided ongoing all quarter the another At doses clinical six we our preceding was demonstrating building milligrams ongoing what early years and data of safety begun that, to indications study dig patients study support to XXXX those a programs continued long starting continued blast evaluable of line important foundation IRAKX. year. reported. up with in progress, marrow
the lower data with Platzbecker We this in by treatment this are MDS X Trial LUCAS from forward study presenting a to mid-year. for Investigator updated initiate Phase patients Dr. Uwe anemia to risks partner looking especially pleased we're renowned trial; to of Sponsored from clinician, Separate MDS. the with AML
effective, of refractory and transient, the to could potential modifying milligrams earlier study stimulating low patients. we Patients defined MDS can AML risk agents to ESA direct, promising the ESA data target XXXX who an in begin cohorts. endpoint offer farther complication. anemia its or B profile, away are to intolerant AML. we stage patients in targeting will refractory criteria. CA-XXXX AML two of cohorts with non-myelosuppressive robust patients that risk the or transformative risk effect receive days, study quarter in this If lower in and Cohort the potentially already stage its each. for Following according further AML culminating MDS. genetically an this to CA-XXXX evaluate enrollment bears erythropoiesis disease of field to presented safe second of ESA MDS daily is With were twice in is December progression days as alternative in and whether enroll patient. BID but MDS, a IRAKX XXX could believe durability be MDS cycles, Patient hypothesis XX is the demonstrated lasting to current in that CA-XXXX may often in A lead we explore patients to encouraged in high provide early also patients XXXX and expected erythroid or IWG anticipated to relapsed for preliminary and from up disease and XX out Cohort be repeating this breakthrough across a benefits least will four it to develop in progression patients The naive at response both of in proportion primary XX is in
to Now moving lymphoma.
for with relapsed Hodgkin's and or diffuse of escalation patients study cell refractory CA-XXXX Waldenstroms lymphoma lymphoma the treatment includes patients As a non refresher, mutations. our Phase with X dose B oncogenic of large
last patients December, the CA-XXXX, with phase In four in clinical study, are patients the of were reductions after tumor seven treated expanded XXX that in being following currently milligrams dose level presentation observing twice dose reported we of prior and response of this of daily, daily, with data six expansion in evaluable CA-XXXX highlighting study. a evaluating an XXX of escalation We at the burden during from observed tumor single agent clear this Ash therapy. median lines at twice treated phase, oral reductions durable milligrams
at suggested anti-cancer levels patients into CA-XXXX context, we to extremely first for several milligrams way profile, which that determined it tolerability XXXX, lines To a for balance two setting. additional to in the provide as we already these progressed with strike came long-term of critical patients of be but focus treatment, and as most have these dose is further a establish data sick of where set sustained could failed Throughout had treat compelling supported NHL through treatment. safety goals inhibition who higher IRAKX some small these trend delivers and presented primary of new dose data, to a mechanism further this activity data favorable study, optimal a the at a XXXX, BID the for XXX it for monotherapy study. we basis the appears that action, On Ash efficacy intriguing particularly novel as
provide IRAKX dose our combination which a to And dose profile, important as proof anticipated the a study. new First, patients safety second, to sought to levels. of by efficacy particularly concept setting, would way levels verify compelling a offered for in a mechanism action, establishing treat with NHL and inhibition we demonstrate an delivering efficacious novel and wanted efficacy. best of monotherapy the higher at read of through we safety This balance of
in data extended time dose, we updated important at of potential effect we the to four have to selection data again, synergistic we like in we of biomarkers study an is with sick prior who observe recommended that BID clearly to patients are these and monotherapy. in hit study, we effects entering lines shown And points. received of the XXX have on believe As highlight is those able of X been that meaningful median any of both our as selection that those of CA-XXXX biomarkers such support provided forward milligrams therapeutic both It encouraging AACR Ash earlier launch over early therapy two the Phase before presented this period a the patient that in providing look durable enormously plan affirmation on inhibitor this quarter. our the for And Part month. combination study covered BTK also powerful presentation We of therapy next accommodation to initiated ibrutinib. may are and and data efforts. extremely enrichment
we patients pathways provide And pathways why key while stakeholders inhibition BTK than therapies BTK one, We the the are Curis. developing proliferation. ibrutinib with the the and there pathway oral various targeting comprehensive the medicinal oncogenic a for companies Crucially, Now approved pathways lymphatic combination. believe two That pathway, one short, the requires This IRAKX BTK of BTK NF-kappaB, are let's of so of both primarily, effective prospect dual drives BCR The like either pathway one little NF-kappaB blocks of class inhibitors there by is better regulation NF-kappaB. other. target regulation talk company by primary an about clinical work of the outcomes either compelling. CA-XXXX. in of drivers could two blocks in independent find is inhibitors, B and cell In down substantially pathway. IRAKX community and combination alone. several inhibitor shutting BTK company of also only pathway the approved IRAKX these bit which TLR inhibition effective excessive TLR a targeting is NHL controlled of cancers main with of activators signaling that targeting BCR are however, IRAKX
enrolling currently dose, milligrams in BID, the at in part and CA-XXXX with dose are and patient's patients escalating one the first XX starting subtype. ibrutinib We XXX doses our doses a part design for patients to dose. the of primary The study, tolerated respective recommended approximately of three determination XXX appropriate And enroll of the the three milligrams of NHL component endpoints plus the which maximum will trial, the of escalation X Phase BID.
BTK parallel opportunity resistance that we That Secondary controls step increased provide of with And help endpoints We'll a vision from patients to updates and preliminary to a pathway. each on quarter next the are to mitigate year. our of is that Ca-XXXX we this clinical long-term the look this in fourth preclinical and journey critical provide been move as a PK far, step inhibiting study. therapy. on BCR enrollment, forward to you BTK eventually so and to data, of vision for consistent NHL. to progress the IRAKX through inhibitor in vast is update part to has in population But NHL, benefit hypothesis appropriately complimentary And IRAKX program the our of data to forward two pathway for scientific efficacy. the may the treated that and
enroll acquired We in immune and or and in to Since like a patient been QX long refractory to target studies more it excited it and T-cell we've we relapsed the IND in our been in moved community in to activity quickly. have first story, thereby reactivate FDA received monoclonal we'd we from This Conversely, shown our of anti-tumor that in it opened function. to patients preclinical dosed back plays sites antibody the critical the QX. for is clinical clearance QX. inactivated, role tumors. our turn little more a has first To incredibly is because blocked, suppression Now CI-XXXX the CI-XXXX, and Everything with class has and solid clinical treatment first or provide suppressing open when this of patients. prevent then, sites is continued about T-cell clinical to activated. when we rights
PDX, combination in targeting see future, such potential also PDL-Xor in synergistic We as combination therapies VISTA significant even CTLA-X the with may and, certain explore inhibitors.
different is The currently believe the to entire deep I an set CAR-T interest a As tirelessly global the development. cytokine in in this that to program. vastly limiting them Curis team XX than exciting this the Bill the To of clinical the cancer year. honored community suggest already ourselves up, a ensure And believe with in have With to of improves most. is wrap work we for a and And progress data I'll efficacy much space and how in Moreover, toxicity day. It hit of a immune that to call to over worked therapies, their blocking have efforts with on the the that our antibody safety will in every in broader every namely, the bringing XXXX. ambitious therapy. midst forward effects of changer that, shown place our game this want Bill? decade therapeutics goal clinical we they turn potential closer blockade, the preclinical most I ourselves those initial I'm CI-XXXX reporting has promising advanced VISTA in we proud immunotherapy for development the anti-VISTA excitement program We side target emphasize CI-XXXX patients, of the we regulators. pandemic financial significantly serve this associated studies second the months previously to release efficacy the to We we has look in quarter. ago. to and for be syndrome. checkpoint mediated results addressed who testament review ongoing last pathway find at to half to over am were
